TYK2 and systemic lupus erythematosus: Deucravacitinib is an orally administered, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that targets its regulatory domain and inhibits signaling pathways mediated by type I interferons as well as the interleukins IL-10, IL-12, and IL-23, which are key cytokines in SLE pathogenesis.